Background: Since January 2011, the Federal Joint Committee (FJC) conducts early benefit assessments (EBA) of newly approved pharmaceutical drugs compared to appropriate standard therapies. The FJC commissions the Institute for Quality and Efficiency in Healthcare (IQEH) to prepare preliminary reports. We aimed to evaluate the extent, impact, and reason for different judgments on added benefit of both institutions.
INTRODUCTION
The Federal Joint Committee ( as an adjunct to FJC to assist with benefit evaluation on healthcare interventions. 2 Since January 2011, FJC conducts early benefit assessment (EBA) procedures of newly approved pharmaceuticals. 3, 4 c 2019 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd These EBA procedures were prompted by a revision of pricing regulations and their reimbursement by Statutory Health Insurance providers in Germany (German short form: AMNOG). 5 FJC evaluates whether a new pharmaceutical has added benefit when compared to appropriate standard therapy. We use the term added benefit to denote a positive patient-relevant treatment effect of a medicinal drug in a controlled clinical study. Pharmaceutical companies are requested to submit dossiers that should include study data on mortality, morbidity, adverse events, or health-related quality of life. 6, 7 In contrast to market authorization, placebo-controlled studies are not considered. If FJC judges an added benefit, then, the pharmaceutical companies can negotiate a price markup with the Statutory Health Insurance. 5 If FJC judges no added benefit, then the Statutory Health Insurance can allocate the marketed drug to an appropriate reference price group. If a proper reference price group is not available, then the annual therapeutic expenses should not exceed those of the proper standard therapy defined by FJC. 8 Figure 1 shows the flow and timeline of the EBA process.
METHODS

Objectives
Our primary objective was to assess the difference of EBA conclusions between FJC and IQEH. Our secondary goals were to evaluate the impact on market withdrawal and identify potential factors that might have contributed to the observed difference.
Classification and evaluation of added benefit
FJC rules of procedure, IQEH methods handbook, the final report on ticagrelor, and the paper by Skipka reported comprehensive information on the classification and evaluation of extent and certainty of added benefit. 6, 7, 9, 10 Knowledge of the EBA backbone may support the understanding of our study. Thus, we provide a snapshot of the concerning definitions and approaches in Tables 1-3. 
Inclusion and exclusion criteria
We included completed procedures. If no dossier was submitted, if there was a change of marketing authorization, and if an evaluation was conducted by FJC only, we did not include the concerning procedures. An added benefit is assigned automatically to orphan drugs for rare diseases unless the annual treatment costs exceed 50 million €. 6, 11 Thus, we excluded orphan drugs. FJC and IQEH may differ in number and content of research questions within a single procedure. To ensure comparable groups, we matched the characteristics of individual subgroups between FJC and IQEH and abandoned those without a matching counterpart.
Quantitative analysis of the difference between FJC and IQEH on the added benefit
We compared IQEH recommendation reports as well as FJC decision reports published from 01 January 2011 to 31 December 2017 on the FJC website. 12 EBA conclusions are built on two mainstays, the extent and the certainty of an added benefit. We use the term "procedure" to combine all actions by FJC referring to a single process regarding the EBA of a pharmaceutical drug. A procedure may contain several subgroup-related research questions. For example, the added benefit may be individually evaluated according to various characteristics of the patients (eg, different age or severity groups) or the intervention (eg, monotherapy and combined therapy). We used the drop-down list provided by the FJC website to filter the retrievals. We transferred the data on EBA from the FJC website to a Microsoft Excel workbook sheet to calculate simple statistics such as total numbers and proportions.
To compare added benefit between IQEH and FJC, we calculated the risk ratio including 95% confidence interval and P value for the overall effect. We used the Cochrane Review Manager 13 and applied MantelHaenszel statistic and fixed-effects model with IQEH versus FJC serving as test versus control and with "no added benefit" acting as the event.
Quantitative analysis of the impact on market withdrawal
After an EBA procedure has been concluded, the respective manufacturer and the Statutory Health Insurance providers determine the reimbursement based on the final FJC decision on added benefit. Manufacturers are keen to negotiate a profitable price that at least allows redeeming the development expenses. A negative EBA decision ("no proof for an added benefit") generally means that price negotiations result in a budget price. 5 As a result, some manufacturers withdrew their products from the German market, though authorisation for marketing was not affected. We conducted an additional search in the web for market withdrawals connected with a negative EBA decision.
Qualitative analysis to identify potential factors contributing to divergent judgments
FJC publishes three main types of documents for any procedure. A first document called "Beschluss" contains the decision by FJC including a statement on added benefit and, if present, on its extent and certainty.
A second document called "Tragende Gründe" defends the decision and explains if FJC does not follow the IQEH recommendation. A third document contains the original IQEH report. We searched these documents and also the FJC rules of procedures 7 and the IQEH methods 6 to identify potential factors that might explain the difference in EBA between FJC and IQEH. Figure 2 and Table S1 show that in the period from 01 January 2011 to 31 December 2017, a total of 331 procedures of EBA were completed by FJC. 12 Of those 331 procedures, 201 procedures were suitable for inclusion and 130 were not applicable. FJC versus IQEH evaluated 481 versus 532 research questions ranging from one to nine within a single procedure. We identified 457 matching research questions suitable for comparing the results of both institutions (Figure 2 ). Figure 3 shows that FJC rated added benefit in 30% (139 of 457) and that IQEH rated added benefit in 22% (101 of 457) research questions. We calculated a Table 4 shows that we identified 28 medicinal products that have been withdrawn from the German market due to adverse EBA decisions.
RESULTS
Quantitative analysis of the difference between FJC and IQEH on the added benefit
Quantitative analysis of the impact on market withdrawal
Qualitative analysis to identify potential factors contributing to divergent judgments
First, IQEH uses a threshold concept to define the rating based on the upper bounds of the confidence interval of the confidence interval of respective relative risk estimators. FJC has stated that it is not following this approach because of inherent value judgements. 14 FJC and its subcommittee might allow more flexibility with applying formalized procedures and stringent criteria.
DISCUSSION
Quantitative analysis of the difference between FJC and IQEH on the added benefit
We found out that FJC and IQEH differed significantly in their EBA conclusions. FJC versus IQEH judged an added benefit in 30% versus 22%
concerning comparable research questions (P = 0.004). FJC and IQEH are legally connected and obliged by law to applying virtually identical data and methods according to the FJC rules of procedure ( § 16
Principles of cooperation with IQEH: (4) If IQEH is commissioned by FJC, cooperation shall be based on these rules of procedure and on the terms of the commission formulated by FJC; § 16d Obligations: IQEH is obligated a) to observe the rules of procedure). 7 Our results are apparently in agreement with those of Ruof who reported a considerable variance in added benefit between FJC and IQEH. 15 In contrast to Ruof, we matched the characteristics of subgroups, which might be regarded as the strength of our study. 
Quantitative analysis of the impact on market withdrawal
The list on market withdrawal shows that negative EBA decisions may affect the medicinal treatment options for patients in Germany. We 24 An author of the review explained that guideline writers who have favored treatment might have based their opinions on a combination of assumptions and data from clinical trials in which patients with mild hypertension were not analyzed separately. 25 We want to point out that Cochrane Collaboration is an organisation of volunteer clinical and methods experts as well as patients from many countries. 26 Herpers reported that IQEH methods prevent the acknowledgement of available evidence. 27 IQEH favors dichotomous endpoints, regards time-to-event endpoints as surrogates except overall survival, and requests two pivotal trials to judge major added benefit. FJC may use a broader range of available evidence.
Qualitative analysis to identify potential factors contributing to divergent judgments
In conclusion, FJC and IQEH differed significantly in their early benefit assessment. A considerable number of pharmaceutical drugs have been withdrawn from the German market due to negative EBA
decisions. FJC appears to be flexible with respect to the input of various interest groups and its respective subcommittee. In contrast, IQEH appears to adhere to stringent criteria. These and other factors might have potentially contributed to the divergent judgments. The present work shows the subjectivity and possible variance inherent in benefit assessment, as the two institutions observe the same rules of procedure.
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